TELIK REPORTS POSITIVE INTERIM PHASE II DATA

Telik reported positive interim data from two ongoing, multicenter Phase II clinical studies evaluating Telcyta (TLK286) in combination with standard chemotherapy in the first-line treatment of advanced non-small cell lung cancer (NSCLC).

The data were presented at the 11th World Conference on Lung Cancer in Barcelona, Spain. One trial is evaluating the triplet combination of Telcyta with standard doses of carboplatin and paclitaxel in patients with Stage IIIB or IV NSCLC. At interim analysis, 35 patients had been enrolled and were evaluable for safety, and 26 of these patients were also evaluable for efficacy. Objective tumor responses were observed in 15 patients (58 percent objective response rate), including one complete response and 14 partial responses and the disease stabilization rate was 92 percent. The regimen was generally well tolerated, the company said.